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ABSTRACT
Background. Multimorbidity [the presence of two or more long-term conditions (LTCs)] is associated with a heightened risk
of mortality, but little is known about its relationship with the risk of kidney events.
Methods. Associations between multimorbidity and major adverse kidney events [MAKE: the need for long-term kidney
replacement therapy, doubling of serum creatinine, fall of estimated glomerular filtration rate (eGFR) to <15 mL/min/1.73 m2
or 30% decline in eGFR] were studied in 68 505 participants from the UK Biobank cohort. Participants were enrolled in the
study between 2006 and 2010. Associations between LTC counts and MAKE were tested using survival analyses accounting
for the competing risk of death.
Results. Over a median follow-up period of 12.0 years, 2963 participants had MAKE. There were associations between LTC
count categories and the risk of MAKE [one LTC adjusted subhazard ratio (sHR) ¼ 1.29, 95% confidence interval (CI) 1.15–1.45;
two LTCs sHR ¼ 1.74 (95% CI 1.55–1.96); and three or more LTCs sHR ¼ 2.41 (95% CI 2.14–2.71)]. This finding was more
pronounced when only cardiometabolic LTCs were considered [one LTC sHR ¼ 1.58 (95% CI 1.45–1.73); two LTCs sHR ¼ 3.17
(95% CI 2.80–3.59); and three or more LTCs sHR ¼ 5.24 (95% CI 4.34–6.33)]. Combinations of LTCs associated with MAKE were
identified. Diabetes, hypertension and coronary heart disease featured most commonly in high-risk combinations.
Conclusions. Multimorbidity, and in particular cardiometabolic multimorbidity, is a risk factor for MAKE. Future research
should study groups of patients who are at high risk of progressive kidney disease based on the number and type of LTCs.
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Multimorbidity [the presence of two or more long-term condi-
tions (LTCs)] is a mounting problem worldwide [1, 2]. It is associ-
ated with polypharmacy [3] and increased treatment burden [4],
and patients often experience poor quality of life [5]. Patients
with multimorbidity are at increased risk of mortality [6, 7], and
there is growing recognition that patterns of multimorbidity, or
the types of LTCs, are linked to adverse outcomes [7]. Although
studies have investigated the associations between multimor-
bidity and mortality, less is known about how the presence of
multimorbidity relates to major adverse kidney events (MAKE).
With reductions in estimated glomerular filtration rate
(eGFR), the risks of death, cardiovascular events and hospitali-
zation rise [8, 9]. Tools such as the Kidney Failure Risk Equation
can help predict which patients are at the highest risk of need-
ing kidney replacement therapy (KRT) [10]. However, the risk of
kidney failure is likely to be more complex than that simply de-
fined by biochemical serum and urinary measurements [11].
Many LTCs and their treatments cause reductions in eGFR,
whereas others develop as complications of chronic kidney dis-
ease (CKD) [12]. Reduced eGFR limits which tests and treatments
can be used for comorbid LTCs such as the use of contrast stud-
ies for coronary angiography, and there are often conflicts be-
tween disease-specific guidelines.
Cardiometabolic LTCs (hypertension, coronary heart disease,
peripheral vascular disease, atrial fibrillation, diabetes, heart
failure and stroke) are particularly associated with adverse out-
comes [13]. Patients with two or more cardiometabolic LTCs
(cardiometabolic multimorbidity) are at high risk of death [7,
14]. Diabetes and hypertension are the two leading causes of
and/or risk factors for MAKE in industrialized nations [12, 15,
16]. However, the impact of the ‘cumulative’ influence of cardio-
metabolic multimorbidity, rather than ‘individual’ cardiometa-
bolic conditions, on MAKE is not well-described.
UK Biobank is a large, prospective, community-based cohort
of participants with extensive phenotyping and biochemical
testing. We hypothesized that in a large population study, we
would observe an association between LTC counts and the fu-
ture risk of MAKE. We further hypothesized that there may be
specific combinations of LTCs that are associated with higher
risk of developing MAKE.
MATERIALS AND METHODS
Study design
UK Biobank recruited 502 503 participants aged 37–73 years be-
tween 2006 and 2010. Biological data and detailed sociodemo-
graphic, lifestyle and medical information were collected at 22
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assessment centres. Ethical approval was provided by the NHS
National Research Ethics Service (16/NW/0274) and all partici-
pants provided written informed consent for data use and link-
age of general practice (GP), hospital episode and national
mortality records. This study is part of UK Biobank project
14151.
Assessments
Blood and urine samples were collected at baseline: serum cre-
atinine, total cholesterol and urine albumin to creatinine ratio
(uACR) were measured at a centralized laboratory. The bio-
chemistry sampling, handling and quality control protocol have
been detailed previously [17]. Serum creatinine was measured
using an enzymatic, isotope dilution mass spectrometry (IDMS)-
traceable method on a Beckman Coulter AU5400 instrument [18]
and the CKD Epidemiology Collaboration formula was used to
calculate eGFR [19].
Participants self-reported their health conditions, medica-
tions and health-related behaviours at baseline. Forty-three
LTCs were considered, as described in previous literature on
multimorbidity in UK Biobank (see list of LTCs, Supplementary
data, Table S1) [7]. All LTCs were taken from self-report other
than CKD (Stages 3–5), which was defined by eGFR of <60 mL/
min/1.73 m2 at baseline. A single blood test was used because all
participants were not acutely unwell at the time of sampling.
LTC counts were categorized into zero LTCs, one LTC, two LTCs
and three or more LTCs. The category ‘three or more LTCs’ was
chosen as the maximum category because the proportion of
participants with more than four LTCs was small.
Cardiometabolic LTCs were categorized in the same way.
Smoking status was divided into three categories: never, cur-
rent or previous. Body mass index (BMI) was ascertained at ini-
tial assessment and used as a continuous variable. Ethnicity
was coded as White, Asian, Black, Chinese, mixed or other (in-
cluding Latin American). Townsend score was used to classify
socio-economic status and used as a continuous variable (a
higher score suggests higher levels of deprivation) [20]. The fre-
quency of alcohol consumption was categorized as: never, spe-
cial occasions only, one to three times a month, one to four
times a week and daily or almost daily. Physical activity was
categorized as none (no physical activity in the last 4 weeks),
low (light ‘do it yourself’ activity only in the last 4 weeks), me-
dium (heavy ‘do it yourself’ and/or walking and/or other exer-
cises for pleasure in the last 4 weeks) and high (vigorous sports
in the last 4 weeks) [21].
Follow-up kidney function
Serum creatinine values were taken from UK Biobank follow-up
testing and linked GP records. We assumed that all UK laborato-
ries report IDMS-traceable creatinine. For individuals with more
than one creatinine value, the value corresponding to the latest
testing date was used. Creatinine values were identified from
GP read codes (Supplementary data, Table S2) [22]. Values were
excluded if the participant had an emergency admission to the
hospital within 5 days of sampling, as the results would be more
likely to be during a period of acute kidney injury (admissions
identified from GP read codes: Supplementary data, Table S2)
[23].
Inclusion criteria
We included participants with creatinine values at baseline and
at follow-up. We included participants with an eGFR of >15 mL/
min/1.73 m2 and not receiving KRT at baseline. KRT was defined
using hospital admission codes, according to a pre-specified al-
gorithm [24].
Study outcomes
The primary outcome was MAKE [25]: the first of the following
endpoints to occur: the need to receive long-term KRT, doubling
of serum creatinine, fall of eGFR to <15 mL/min/1.73 m2 or 30%
decline in eGFR from baseline. This definition is based on previ-
ous work from the Chronic Kidney Disease Prognosis
Consortium [26, 27]. All-cause mortality before MAKE was con-
sidered as a competing risk (an event that prevents the primary
outcome from occurring) [28, 29]. We excluded participants who
died or who had MAKE in the first 12 months of follow-up. This
landmark analysis sought to exclude participants whose condi-
tion was deteriorating rapidly at recruitment [30]. The follow-up
period started 12 months after the date of the first assessment
and ended with the date of death, date of MAKE or end of data
collection (26 April 2020), whichever occurred first.
Statistical analysis
Demographic, physiological, prescribing and laboratory charac-
teristics were described across LTC count categories, using
medians and interquartile ranges (IQRs) for continuous varia-
bles and percentages for categorical variables. Differences in the
distribution of these characteristics were tested using analysis
of variance for continuous variables and Chi-squared tests for
categorical variables. The characteristics of participants who
had MAKE were compared with those who did not. The charac-
teristics of participants were compared based on the availability
of follow-up data: those with and without creatinine results,
those with and without linked GP data, those with linked GP
data with and without creatinine results, and those with and
without creatinine results via UK Biobank.
Cumulative event incidence plots and Fine and Gray subdis-
tribution hazard models were used to examine the relationship
between LTC count categories and outcomes, with all-cause
mortality the competing event [28, 29]. A competing risks ap-
proach was chosen over a Cox model as the preferred approach
for prognostication of kidney function in the presence of a com-
peting event such as the risk of death before MAKE [28, 31].
Participants with zero LTCs were used as the reference group.
Subdistribution hazard models generated subhazard ratios
(sHRs), with adjustments for confounding variables and 95%
confidence intervals (CIs). Confounding variables in the stan-
dard model were age, sex, baseline eGFR, uACR, ethnicity, total
cholesterol, BMI, smoking status and physical activity levels.
These variables were chosen because there are associations
with MAKE [12]. The proportional hazards assumption was
tested using Schoenfeld residuals. Complete cases were used,
which was acceptable because the proportion of participants
with missing data was <5%. Analyses were repeated using car-
diometabolic LTC counts. Additional analyses were performed
adding adjustments for blood pressure and alcohol use. Blood
pressure and alcohol use were not included in the standard
model because hypertension and alcohol problems were in-
cluded as self-reported LTCs. Adjustments were not made for
the use of medications such as renin–angiotensin–aldosterone
system blockers because of the risks of indication bias. A sensi-
tivity analysis was performed using event plots and propor-
tional hazard Cox models with participants censored at their
date of death. These analyses were performed for total LTC
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counts and for cardiometabolic LTC counts with adjustments as
in the standard model above.
Combinations of LTCs were identified and the associations
between different LTC combinations and MAKE were studied.
Competing risks models were used to identify which individual
LTCs were associated with MAKE and these were used to iden-
tify all possible combinations of LTCs. To reduce the risk of mul-
tiple comparisons, we restricted our analysis to individual
conditions and combinations of conditions present in >0.1% of
the cohort (i.e. >68 subjects). This technique was performed for
the LTC count categories two LTCs and three or more LTCs. All
models were adjusted as in the standard model above.
Participants with zero LTCs were used as the reference group.
We reported event numbers and sHRs with 95% CIs for individ-
ual LTCs and LTC combinations associated with MAKE.
All analysis was conducted using R software version 3.6.0.
Ethics approval
UK Biobank has full ethical approval from the NHS National
Research Ethics Service (16/NW/0274).
RESULTS
Participant inclusion
A total of 68 505 participants met the inclusion criteria (see par-
ticipant flow chart, Supplementary data, Figure S1). From the
original UK Biobank cohort, 469 356 of 502 503 participants had
a creatinine result at baseline. Of the 230 105 participants with
linked GP data, 57 992 had one or more creatinine results during
the follow-up period. A total of 16 579 participants had follow-
up creatinine values recorded through UK Biobank. A total of
580 387 follow-up creatinine measurements were available.
Thirty-four participants were excluded because their eGFR was
<15 mL/min/1.73 m2 or they were on KRT at baseline. Forty-nine
participants were excluded because they died or had MAKE in
the first 12 months of follow-up.
Baseline characteristics
Table 1 demonstrates the baseline characteristics of the in-
cluded participants by LTC count categories. Compared with
participants with zero LTCs, those with more LTCs tended to be
older, female, of White ethnicity, residing in areas of greater
socio-economic deprivation, smokers, with less alcohol con-
sumption, lower physical activity levels, higher BMI, higher sys-
tolic blood pressure, higher uACR, lower total cholesterol, lower
eGFR and more were prescribed antihypertensives and statins.
The participants with and without linked GP data and those
with and without follow-up data from UK Biobank and GP
records were similar (Supplementary data, Tables S3–S6). In
those with and without follow-up data, participants had similar
numbers of LTCs and the prevalence of diabetes was similar.
Participants of Black and Asian ethnicities were under-repre-
sented and those with hypertension were over-represented.
Outcomes
During a median (IQR) follow-up period of 12.0 years (11.2–
12.3 years), 2963 participants had a MAKE event and 3338 died.
Those with MAKE had more LTCs and more cardiometabolic
LTCs (Table 2). Those with MAKE were more likely to be older,
smokers, from areas of greater socio-economic deprivation,
with lower consumption of alcohol, lower physical activity
levels, higher BMI, higher systolic blood pressure, higher uACR,
lower baseline eGFR, lower total cholesterol and proportionally
more were prescribed antihypertensives and statins.
Cumulative incidences of MAKE and mortality were higher
in participants with more LTCs (Figure 1). At the end of the fol-
low-up period, 509 participants (2.3%) in the zero LTC category
had MAKE, compared with 785 participants (3.5%) in the one
LTC category, 738 participants (5.5%) in the two LTCs category
and 931 participants (9.2%) in the three or more LTCs category.
When only cardiometabolic LTCs were considered, 1267 partici-
pants (2.8%) in the zero LTC category had MAKE, compared with
1002 participants (5.5%) in the one LTC category, 522 partici-
pants (13.0%) in the two LTC category and 172 participants
(23.7%) in the three or more LTC category (Figure 2).
Competing risks analysis
The proportional hazards assumption was upheld. Associations
were observed between LTC count categories and the risk of
MAKE over the follow-up period (Table 3). A dose–response rela-
tionship was seen in both unadjusted and adjusted competing
risks analyses. In the standard model, participants with three or
more LTCs were more than twice as likely to develop MAKE
than those with zero LTCs (sHR ¼ 2.41, 95% CI 2.14–2.71). For
participants with three or more cardiometabolic LTCs, the risk
was more than five times greater than those with zero LTCs
(standard model sHR ¼ 5.24, 95% CI 4.34–6.33). The relationship
between the number of conditions and MAKE appeared to be cu-
mulative, whether all LTCs or just cardiometabolic LTCs were
considered. Results were similar when Cox proportional haz-
ards models were fitted, but with smaller effect sizes, including
for cardiometabolic LTCs (Supplementary data, Figures S2 and
S3 and Supplementary data, Tables S7 and S8). Results were
similar when frequency of alcohol use was added as a covari-
able of interest (Supplementary data, Table S9). Most MAKE
events were related to a decline of 30% in eGFR with 67 partici-
pants needing to initiate KRT (Supplementary data, Table S10).
Competing risks analysis of each component of the MAKE defi-
nition confirmed associations between increasing LTC count
category and each component, except KRT initiation (perhaps
because of small event numbers). About 65.9% of those with
MAKE defined from biochemical changes had blood samples
that confirmed the decline in kidney function was sustained.
Combinations of LTCs
Fourteen LTCs were present in >0.1% of the cohort and had
associations with MAKE, and so were considered for potential
combinations of LTCs (Table 4). For participants with two LTCs,
10 different combinations of the 14 individual LTCs were pre-
sent in >0.1% of the cohort and 6 had associations with MAKE
(Table 4). For participants with three or more LTCs, 29 different
combinations of individual LTCs had individual associations
with MAKE and 20 of these were present in >0.1% of the cohort
(Table 4). For participants with two LTCs, hypertension featured
in all of the combinations and for those with three or more
LTCs, hypertension, diabetes, coronary heart disease and
treated dyspepsia featured most commonly.
DISCUSSION
In this study of 68 505 UK Biobank participants, we found an as-
sociation between increasing LTC counts and the risk of MAKE.
This finding was consistent for all LTCs, and the association
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with cardiometabolic multimorbidity was observed to have
higher effect sizes. We identified combinations of LTCs that
were associated with extremely high risk of MAKE. Diabetes and
hypertension predominate in these high-risk groups, and this is
not an unexpected finding. However, the substantial cumula-
tive link and the magnitude of the association between combi-
nations of cardiometabolic LTCs and MAKE have not been
investigated in this easily understood manner before, and it is
more descriptive of the clinical problem faced by clinicians car-
ing for at-risk patients.
Our study findings are consistent with a previous study in
which increasing LTC counts were associated with the need for
dialysis in patients with CKD [32]. However, our approach was
more comprehensive, including participants with normal and
abnormal kidney function at baseline. Notably, >90% of the par-
ticipants who developed MAKE did not have CKD at baseline.
We have therefore shown that cardiometabolic multimorbidity
is a risk factor for MAKE, even in the absence of CKD at baseline.
Our definition of MAKE included a 30% fall of eGFR, which is an
approach consistent with recommendations emerging from the
Table 2. Baseline characteristics by MAKE
Baseline characteristics No MAKE, n¼ 65 542 (95.7%) MAKE, n¼ 2963 (4.3%)
Age, median (IQR), years 58.0 (51.0–63.0) 61.0 (55.0–66.0)
Sex, n (%)
Female 35 215 (53.7) 1620 (54.7)
Male 30 327 (46.3) 1343 (45.3)
Ethnicity, n (%)
White 63 339 (96.6) 2839 (95.8)
Asian 727 (1.1) 50 (1.7)
Black 418 (0.6) 23 (0.8)
Mixed 326 (0.5) 12 (0.4)
Chinese 182 (0.3) 9 (0.3)
Other 342 (0.5) 21 (0.7)
Socio-economic status based on Townsend score, median (IQR) 2.3 (3.8, 0.1) 2.0 (3.6, 1.0)
Frequency of alcohol consumption, n (%)
Never 4904 (7.5) 348 (11.7)
Special occasions only 7229 (11.0) 490 (16.5)
One to three times a month 7340 (11.2) 327 (11.0)
Once or twice a week 17 239 (26.3) 792 (26.7)
Three or four times a week 15 612 (23.8) 528 (17.8)
Daily or almost daily 13 129 (20.0) 471 (15.9)
Physical activity, n (%)
None 4485 (6.8) 355 (12.0)
Low 2410 (3.7) 171 (5.8)
Medium 51 719 (78.9) 2246 (75.8)
High 6624 (10.1) 158 (5.3)
Smoking status, n (%)
Never 36 437 (55.6) 1412 (47.7)
Current 6587 (10.1) 421 (14.2)
Previous 22 278 (34.0) 1110 (37.5)
BMI, median (IQR), kg/m2 26.8 (24.2–30.0) 28.3 (25.3–32.2)
Systolic blood pressure, median (IQR), mmHg 137.0 (126.0–150.0) 143.0 (131.0–157.0)
CKD (eGFR <60 mL/min/1.73 m2), n (%) 1264 (1.9) 217 (7.3)
Diabetes mellitus, n (%) 2817 (4.3) 607 (20.5)
Hypertension, n (%) 18 023 (27.5) 1442 (48.7)
LTCs, n (%)
0 21 839 (33.3) 509 (17.2)
1 21 809 (33.3) 785 (26.5)
2 12 657 (19.3) 738 (24.9)
3 or more 9237 (14.1) 931 (31.4)
Cardiometabolic LTCs, n (%)
0 44 439 (67.8) 1267 (42.8)
1 17 062 (26.0) 1002 (33.8)
2 3487 (5.3) 522 (17.6)
3 or more 554 (0.8) 172 (5.8)
Baseline eGFR, median (IQR), mL/min/1.73 m2 93.0 (83.4–99.9) 90.1 (79.6–96.6)
Urine ACR, median (IQR), mg/mmol 0.0 (0.0–0.6) 0.0 (0.0–1.5)
Total cholesterol, median (IQR), mmol/l 5.7 (4.9–6.4) 5.4 (4.5–6.2)
Antihypertensives prescribed, n (%) 15 154 (23.1) 1366 (46.1)
Statin prescribed, n (%) 10 955 (16.7) 1022 (34.5)
P < 0.001 for all variables apart from sex (0.31) and ethnicity (0.065) (Kruskal–Wallis test for continuous variables and Chi-squared tests for categorical variables).
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National Kidney Foundation and the US Food and Drug
Administration workshops [26, 27]. This surrogate endpoint for
the development of kidney failure is important because it iden-
tifies patients before the late outcome of KRT. Studies by
Bowling et al. [33] and Tonelli et al. [34] have shown that the pat-
tern of LTCs is a risk factor in the association between multi-
morbidity and death in patients with CKD. Our analysis
meaningfully extends this work by demonstrating that the pat-
tern of LTCs is also linked to MAKE.
As expected, cardiometabolic LTCs and CKD were associated
with MAKE. There were also associations with schizophrenia
and bipolar disorder, but there were insufficient participants
with these conditions for them to feature in the high-risk com-
binations of LTCs. It is likely that patients with mental health
conditions are under-represented in UK Biobank. If a similar
study was performed in the general population, high-risk
groups of patients with combinations of physical and mental
health problems may be identified. Some non-cardiometabolic
FIGURE 1: Cumulative incidence of outcomes by LTC count category.
FIGURE 2: Cumulative incidence of outcomes by cardiometabolic LTC count category.
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LTCs were identified in the high-risk combinations: dyspepsia,
cancer, and psoriasis or eczema. Medications used in these con-
ditions may explain the link, or other unidentified mechanisms
could be responsible. Dyspepsia has been identified in high-risk
combinations of LTCs in a similar analysis studying mortality
risk in patients with diabetes [35]. Although some associations
with proton-pump inhibitor use and future risk of CKD have
been described [36], it is unclear why these associations exist.
An important strength of our study was the inclusion of
many participants with extensive phenotyping and a follow-up
period that was adequate to observe the development of MAKE.
The use of competing risks analysis is appropriate for studying
the prognostication of kidney function, where death is a more
frequent event than the kidney outcomes of interest [28].
Our study has some limitations. A large proportion of UK
Biobank participants were healthy volunteers and there was
under-representation of non-White and socio-economically de-
prived populations [37]. Analysis in a cohort with greater ethnic
diversity may be necessary to confirm the generalizability of
our findings to other countries. LTCs and covariates were only
taken at baseline and we have not taken into account changes
during follow-up because we sought to estimate the risk of pro-
gressive kidney disease from a single point in time. Our study
used a select population because most of the UK Biobank cohort
did not have follow-up biochemistry. Although there was a risk
of selection bias (survival and ascertainment), we showed that
the populations with and without follow-up biochemistry had
similar characteristics. Single blood tests were used to quantify
eGFR without confirmatory testing, which was deemed to be ac-
ceptable because participants were assumed to be stable at
baseline assessment. Follow-up results were excluded if they
were taken close to hospital admissions, but it is possible that
we were unable to detect all cases of acute kidney injury. The
use of self-reported LTCs is a potential limitation. However, par-
ticipants were supported by a nurse in the assessment process
to improve accuracy, and self-report has been found to be a
valid method [38, 39].
Potential impact
Our identification of combinations of LTCs that associate with
MAKE is novel, and these high-risk groups must be studied fur-
ther to identify how their risk can be reduced. Clinical leaders
have highlighted that multimorbidity, rather than comorbidity,
is a major global health issue and suggest that identifying clus-
ters of conditions with clinical impacts is a research priority
that could help improve the treatment of these complex
patients [1, 2, 40]. Clinical guidelines should emphasize the im-
portance of monitoring kidney function for patients with cardi-
ometabolic multimorbidity, including those with normal kidney
function. Potential interventions in these patients are intensive
blood pressure and glycaemic control, lifestyle modification or
planning of KRT. These interventions must always consider the
priorities of patients, acknowledging their treatment burdens,
which may already be significant.
Our study has demonstrated that multimorbidity, and in
particular cardiometabolic multimorbidity, is a risk factor for
MAKE, even in the absence of CKD. We have highlighted combi-
nations of LTCs that are associated with high risk of MAKE in
which more research is necessary to understand how risk re-
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